Experimental Human Pneumococcal Carriage: Asthma and immune function
Pneumococcal bacteria often live harmlessly in the noses of healthy people. In some cases, however, they can cause serious chest infections, pneumonia, or sepsis. People living with asthma are known to have a higher risk of developing illness from these bacteria, but doctors do not yet fully understand why. In this study, researchers at the Liverpool School of Tropical Medicine are investigating how asthma affects the body's natural defences. Non-smoking adults aged 18 to 50 with mild, well-controlled asthma receive a few drops of live bacteria into their nose. Over several weeks, the team collects blood and nose samples to track the immune response. Participants receive full safety support throughout, including a home thermometer and antibiotics to keep on hand. While there is no direct health benefit from taking part, the findings could help researchers design better vaccines and treatments in the future.
At a glance
What is this study about?
Pneumococcal bacteria are very common. Many healthy adults carry them quietly in their nose or throat without ever feeling ill. In fact, carrying these bacteria naturally can sometimes help train the immune system to fight off future infections. However, the same bacteria can also cause dangerous illnesses, such as chest infections, pneumonia, and blood poisoning, especially in people with sensitive airways.
Doctors know that people with asthma are more likely to catch pneumococcal infections, but the exact reasons remain unclear. To investigate this, researchers use a carefully managed approach known as a carriage study. By placing a small, safe amount of bacteria into the nose of volunteers with asthma, scientists can watch how the immune system responds in real time.
Finding out how the immune system handles these bacteria could uncover why people with asthma are more vulnerable to lung infections. In the long run, this valuable knowledge could help medical teams develop better vaccines and preventative medicines to protect people living with asthma.
Key takeaways
- The study explores how mild asthma affects the immune system's response to common nose bacteria.
- Open to non-smoking adults aged 18 to 50 with well-controlled asthma.
- Involves receiving nose drops of live bacteria and attending follow-up visits for blood and nose swabs.
- Full safety support, including antibiotics to keep at home and 7-day medical access, is provided.
- Participation is completely voluntary with no direct personal health benefits.
Who may be eligible?
This study is open to adults aged 18 to 50 who have mild to moderate, well-managed asthma. You must be able to carry out your daily activities without major restriction, speak fluent English, and have your own mobile phone so the research team can keep in regular contact with you.
To ensure your safety, you cannot take part if you currently smoke, have smoked in the last six months, or have a history of heavy smoking. You will also not be able to join if you have had an asthma flare-up requiring steroid tablets or antibiotics within the past 28 days, or if you have had more than one flare-up in the past year.
Because pneumococcal bacteria can spread to others, you cannot join if you live or work closely with people at high risk of infection. This includes children under five years old and adults with weakened immune systems.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you aged between 18 and 50?
- Do you have a doctor's diagnosis of mild to moderate, well-controlled asthma?
- Are you a non-smoker who has not smoked in the past six months?
- Has it been at least 28 days since your last asthma flare-up or course of steroid tablets?
- Can you confirm you do not live or work with children under five or people with weakened immune systems?
What does participation involve?
If you decide to take part, the first stage lasts about 4 to 5 weeks. During an initial visit, the team will place a few drops of liquid containing the bacteria into your nose. Over the next month, you will attend appointments to have blood samples and gentle nose swabs collected so researchers can track your immune response. Some participants may be invited back after 6 to 12 months for a second stage to see if their bodies have built lasting immunity. You will receive a thermometer and a safety pack of antibiotics to keep at home just in case, and medical staff are on hand 7 days a week to provide care if you feel unwell.
Potential risks and benefits
Locations (1)
- Royal Liverpool University HospitalApproximateLiverpool, England
Common questions
Will taking part give me severe pneumonia?
The risk is very low. Researchers use a tiny, controlled dose of bacteria, monitor your health closely, and provide antibiotics for you to keep at home just in case you develop any symptoms.
Does having the bacteria put in my nose hurt?
No. The bacteria are delivered as simple liquid drops into your nose, which feels very similar to using ordinary nasal drops.
Can I pass these bacteria to my friends or family?
It is possible to pass the bacteria to others through close contact. For this reason, anyone who lives or works closely with young children or people with weakened immune systems cannot take part.
What happens if my asthma flares up during the trial?
You will have direct telephone access to the research medical team 7 days a week, and they will arrange prompt care and treatment if your asthma symptoms worsen.
Can I leave the study early if I change my mind?
Yes. You can leave the study at any point without giving a reason, and your routine NHS care will not be affected in any way.
How to find out more
Seher Zaidi
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.